<DOC>
	<DOCNO>NCT02383927</DOCNO>
	<brief_summary>Phase II study investigate antitumor activity term ORR tipifarnib subject advance tumor carry HRAS mutation standard curative therapy available .</brief_summary>
	<brief_title>Phase II Study Tipifarnib Squamous Head Neck Cancer With HRAS Mutations</brief_title>
	<detailed_description>This Phase II study investigate antitumor activity term ORR tipifarnib subject locally advance , unresectable metastatic , relapse and/or refractory tumor carry HRAS mutation curative therapy available . Subject information available tumor HRAS status previously generate eligible . All subject must consent provide least 10 tumor slide prior diagnostic biopsy retrospective test RAS gene status central facility . Subjects enrol two nonrandomized cohort : - Cohort 1 : Malignant thyroid tumor HRAS mutation . - Cohort 2 : Squamous Head Neck Cancer HRAS mutation .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>histologically cytologically confirm diagnosis thyroid cancer ( cohort 1 ) squamous head neck cancer ( cohort 2 ) curative therapy available . tumor carry missense HRAS mutation Subject consent provide least 10 unstained tumor slide retrospective test HRAS gene tumor status Subject measurable disease accord RECIST v1.1 relapse refractory prior therapy . At least 2 week since last systemic therapy radiotherapy regimen prior enrolment ECOG PS 0 1 Acceptable liver function Acceptable renal function Acceptable hematologic status Prior treatment FTase inhibitor History relevant coronary heart disease myocardial infarction within last 3 year , NYHA Grade III great congestive heart failure , cerebrovascular attack within prior year , serious cardiac arrhythmia require medication except atrial fibrillation . Known uncontrolled brain , leptomeningeal epidural metastasis ( unless treat well control least 4 week prior Cycle 1 Day 1 ) . Controlled brain metastasis require continuous high dose corticosteroid use within 4 week Day 1 . Nontolerable &gt; Grade 2 neuropathy evidence unstable neurological symptom within 4 week first dose Major surgery , diagnostic surgery , within 4 week prior first dose , without complete recovery . Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy . Known infection HIV , active infection hepatitis B hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>